The involvement of AHR/CYP1A1 activation is suggested in the development of non-alcoholic fatty liver disease (NAFLD) and the consequent onset of diabetes [59]. This evidence concerns the gene CYP1A1 and metabolic dysfunction-associated steatotic liver disease.